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Abstract Sulforhodamine 101 (SR101) is widely used for
astrocyte identification, though the labeling mechanism
remains unknown and the efficacy of labeling in different brain
regions is heterogeneous. By combining region-specific iso-
lation of astrocytes followed by transcriptome analysis, two-
photon excitation microscopy, and mouse genetics, we iden-
tified the thyroid hormone transporter OATP1C1 as the
SR101-uptake transporter in hippocampus and cortex.
Keywords Astrocyte  Cell-specific markers 
Transcriptome analysis
Introduction
The red fluorescent xanthene derivative sulforhodamine 101
(SR101) has been introduced to neuroscience in 1985 as a
dye for activity-dependent labeling of synaptic terminals
(Lichtman et al. 1985). Since then, different labeling proto-
cols have been used and thus SR101 was shown to stain
different cell types in various regions of the brain with
considerable species difference. Reports of labeled cell
population range from rabbit oligodendrocytes in the retina
(Ehinger et al. 1994) to turtle spinal cord neurons (Mui et al.
2012). In 2004, Nimmerjahn and colleagues identified
SR101 as a selective marker for cortical astrocytes in vivo
after bolus injection or topical application to the cortical
surface (Nimmerjahn et al. 2004). Later, SR101 was also
confirmed as a valid method in acutely isolated hippocampal
and cortex slices (Ikegaya et al. 2005; Kafitz et al. 2008).
However, the molecular mechanism of the cell-specific
SR101-labeling remained unknown. Initially, it was
hypothesized that gap-junction hemichannels were involved
in the labeling process (Nimmerjahn et al. 2004); however,
astrocytes from Cx30-/-Cx43fl/fl:hGFAP-Cre mice
(Cx30-/-Cx43-/-, double knockout) that lack most of the
gap-junction protein were effectively labeled with SR101
(Pannasch et al. 2011). Recently, pharmacological profiling
of SR101 uptake with inhibitors of organic anion transport
led to the conclusion that SR101 was likely to be actively
transported into astrocytes via an organic anion-transporting
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polypeptide (OATP), although the identity of the responsible
transporter remained unknown (Schnell et al. 2012).
Furthermore, the use of SR101 has been compromised
by recent reports of neuronal SR101-labeling that occurs
under pathophysiological conditions such as NMDA
receptor activation or ischemia (Thompson et al. 2006;
Thompson et al. 2008). Moreover, the side effects of
SR101, including chemical LTP, have been reported (Kang
et al. 2010; Garaschuk 2013). Therefore, an understanding
of the molecular mechanism of SR101 uptake is crucial for
its future application as a marker of astrocyte subtypes.
In contrast to the hippocampus, unequivocal identifica-
tion of astrocytes by SR101 is not possible in the ventral
lateral medulla (VLM) of the brainstem, which contains
important neurons of the respiratory network. In this region
as well as in the rat spinal cord, SR101 has been found to
label neurons and astrocytes (Cina and Hochman 2000;
Schnell et al. 2012) indicating that a region-specific het-
erogeneity of astrocytes underlies the lower SR101-uptake
efficiencies in the more caudal brain regions.
Based on the pharmacological profile of the SR101-
labeling (Schnell et al. 2012) we hypothesize that candidate
genes from SLC(O) solute carrier families display elevated
mRNA expression levels in forebrain versus brainstem
astrocytes. To test for this, we captured EGFP-expressing
astrocytes from brainstem (poor SR101 uptake) and hip-
pocampus as well as cortex (both efficient SR101 uptake)
from hGFAP-EGFP transgenic mice (Nolte et al. 2001) by
fluorescence-activated cell sorting (FACS) and performed




Experiments were performed on acute brain slice prepa-
rations of transgenic mice [postnatal day 8–43 (P8–P43),
male and female] expressing enhanced green fluorescent
protein in astrocytes [TgN (hGFAP-EGFP) GFEC-Fki;
(Nolte et al. 2001)] or on Slco1c1 knockout mice (Mayerl
et al. 2012). Animals were held and bred in the animal
facilities of the University Hospital Go¨ttingen and the
Leibniz Institute for Age Research in accordance with
guidelines of the German Physiological Society as well as
the regulations of the State of Lower Saxony and the
Federal Republic of Germany.
Slice preparations
Acute transversal slices from brainstem and hippocampus
were prepared as described previously (Ha¨rtel et al. 2007;
Schnell et al. 2012). In some experiments, parasagittal
slices were cut to compare the SR101 staining along the
rostral–caudal extension of the cortex. To obtain acute
slices, animals were killed by decapitation under deep
diethyl-ether anesthesia. The brains were removed from the
skull and the isolated hippocampi and brainstem were
placed in ice-cooled, carbogen-saturated (95 % O2, 5 %
CO2) artificial cerebrospinal fluid (aCSF) containing
118 mM NaCl, 3 mM KCl, 1.5 mM CaCl2, 1 mM MgCl2,
1 mM NaH2PO4, 25 mM NaHCO3, and 30 mM D-glucose.
The osmolarity was 325–335 mosm/l and the pH adjusted
to 7.4. The isolated brain part was glued with cyanoacryl
glue (Loctite Deutschland GmbH) to an agar block and
mounted in a vibroslicer (VT 1200S, Leica). Slices of
250–400 lm were cut and stored in oxygenated aCSF at
room temperature for at least 30 min before staining. For
imaging experiments, slices were transferred to the
recording chamber after the staining procedure (see below).
Slices were kept submerged by a nylon fiber grid and
continuously perfused with aCSF at a flow rate of 5–10 ml/
min.
Sulforhodamine 101 staining protocol
Sulforhodamine 101 (SR101) labeling was performed
using the standard protocol as described earlier (Kafitz
et al. 2008; Meier et al. 2008; Schnell et al. 2012). Slices
were incubated for 20 min at 34 C in carbogenated aCSF
containing 1 lM SR101 followed by 10 min in carbogen-
ated aCSF at 34 C without SR101 for removal of excess
dye from the extracellular space. For the T4/SR101 com-
petition studies, L-Thyroxine (T4; 1–10 lM) was co-
applied with SR101 only during the 20 min incubation
period.
Drugs
Electrolytes for aCSF (see above) were purchased from
Sigma-Aldrich and Merck chemicals. Drugs were stored in
concentrated stock solution at -20 C. The 1 mM L-thy-
roxine sodium salt pentahydrate (Sigma-Aldrich; T2501)
stock solution was prepared with 0.1 N NaOH and the
0.5 mM SR101 (Sigma-Aldrich, S7635) stock solution was
made with distilled water.
Fluorescence imaging using multifocal two-photon
excitation microscopy
For detection of EGFP- and SR101 fluorescence, we used a
two-photon microscope (TriMScope, LaVision BioTec)
with non-descanned detection by GaAsP photomultipliers
(Hamamatsu). Two-photon excitation was achieved with a
Ti:Sapphire Laser (SpectraPhysics MaiTai BB) at 800 nm.
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Fluorescence signals of hGFAP-EGFP expressing astro-
cytes were detected through a 531/40 nm band pass
emission filter, whereas SR101 fluorescence was detected
through a 641/75 nm band pass emission filter (AHF
Analysentechnik AG). To allow quantitative comparison of
the SR101 intensity between controls and drug treatments,
all image parameters, pixel dwell time and number,
detector gain as well as laser power were identical for a
particular set of experiments. Cell counting was performed
in a defined volume that was scanned with 2 lm step
z-stacks (100 lm in total) using a piezo-focus (Physik In-
strumente). All settings were controlled by ‘‘Imspector’’
software (LaVision BioTec).
For quantification of SR101 fluoresence, ‘‘Imspector’’
images were exported to TIFF format. After deconvolution
with Autoquant software (MediaCybernetics) using the
theoretical point-spread-function (adaptive PSF, ten itera-
tions), further analysis was performed with the Imaris
software package (Bitplane) using the ‘‘spots’’ feature of
the ‘‘surpass’’ view mode. In this mode, astrocytes were
identified by their EGFP fluorescence in the green channel
and a spherical 3D volume (spot) of 6 mm diameter was
assigned to the soma of each EGFP-positive cell astrocytes.
To quantify the SR101-labeling, the green channel was
turned off. The ‘‘recentering’’ function was used to correct
the position of the spot in the red SR101 channel. If this was
impossible or if the SR101 intensity was not differing from
the surrounding background signal, the particular cell was
counted as an SR101-negative cell. The parameter ‘‘SR101-
positive astrocytes (%)’’ was calculated by dividing the
number of both SR101-positive and EGFP-positive cells by
the total number of EGFP-positive cells multiplied by 100.
SR101- and EGFP-fluorescence intensities of individual
cells were derived from the median intensity of the assigned
spot and averaged for each slice individually. The param-
eter ‘‘SR101 intensity (% of EGFP fluorescence)’’ was
calculated by dividing the SR101 intensity by the EGFP-
fluorescence intensity multiplied by 100.
Analysis of imaging data
Fluorescence intensity and cell number are presented as
means and standard error (SEM). One-way ANOVA tests
with multiple comparisons versus control group (Bonfer-
roni t test) were used to determine statistical significance,
considering P B 0.05 as significant. Statistical calculations
were performed in SigmaPlot (Systat Software GmbH).
Fluorescent activated cell sorting (FACS) of EGFP-
positive astrocytes
Brains were removed from P10 old hGFAP-EGFP mice
(Nolte et al. 2001) and sectioned in oxygenated aCSF at
4 C with a vibratome to obtain 150 lm thick slices.
Cortex, hippocampus and brainstem were subsequently
dissected and processed by incubation with freshly pre-
pared Papain solution for 20 min at 37 C as suggested by
the manufacturer (Worthington). Samples were homoge-
nized by gentle trituration with a 1 ml glass pipette, fol-
lowed by staining of nuclei with cell-permeable nuclear
Hoechst 33,342 dye (Sigma) at 37 C for 10 min. Cells
were filtered through 40 lm nylon cell strainer before
sorting. FACS isolation of EGFP-positive astrocytes was
done using a FACS Aria II (Becton–Dickinson) and gates
were set according to control samples for each brain region
from wild-type mice. First, forward and side scatter was
used to deplete for small sized cellular debris, followed by
selection of Hoechst 33,342 and EGFP double-positive
cells which were directly sorted into RLT lysis buffer
(Qiagen) and frozen at -20 C until use.
Amplification of RNA and generation of libraries
and Illumina sequencing
For generation of libraries for Illumina sequencing from
pools of sorted EGFP-positive astrocytes, we modified an
established linear amplification protocol using the DNA-
dependent RNA polymerase from bacteriophage T7
(Rossner et al. 2006). Therefore, we first isolated RNA
using RNA easy microcolumns (Qiagen) according to
manufacturer protocols except of RNA elution, which was
done by adding 100 ll H2O followed by ethanol precipi-
tation with NH4Ac (f.c. 2.5 M) and pellet paint (Invivogen)
as carrier. The precipitate was air-dried and resolved in
2 ll of freshly diluted oligo-dT T7-B primer (2 lM).
cDNA was synthesized in a total volume of 4 ll using a
2 9 pre-mix of Superscript III polymerase (1 h 50 C)
according to manufacturer’s recommendations (Invitro-
gen). Double-stranded (ds) cDNA was initiated by adding
RNAseH and DNA PolI in a volume of 26 ll as described
(Rossner et al. 2006). Purification of ds cDNA with GFX
columns (GE Healthcare) and T7-mediated antisense RNA
amplification (T7 Megascript Kit, Ambion) and aRNA
purification were essentially performed as described
(Rossner et al. 2006). Second-round cDNA synthesis was
initiated with 2 ll of a random hexamer primer (100 lM)
with hairpins flanking a sequence stretch for PCR ampli-
fication (Dec1-Hairpin-N9), which was shown to suppress
false-positive PCR products (Adli et al. 2010) in a volume
of 10 ll with Superscript III for 10 min at 25 C followed
by 50 min at 50 C. RNA was subsequently degraded by
adding NaOH (25 min at 68 C) and neutralized by HCl
(1 ll of a 25 mM solution each). Advantage Taq poly-
merase (Clontech) and primer B-short were used to gen-
erate ds cDNA in a volume of 100 ll (according to the
manufacturer’s recommendations) and purified using
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Nucleo-Spin columns (Macherey & Nagel). Pool-identify-
ing barcodes were introduced by PCR using PWO poly-
merase (Roche) and Code_Dec1 c40 and B-short as
primers for ten cycles in a volume of 20 ll and an
annealing temperature of 58 C. PCR products were ana-
lyzed by agarose gel electrophoresis and combined to a
final sample for the attachment of Illumina sequencing
adaptors by five cycles of PCR with PWO (Roche) and 1 ll
of each primer (Illumina-for and Illumina-B-rev at 10 lM)
in a volume of 100 ll. Size selection (200–400 bp) of the
final PCR product was done by agarose gel electrophoresis
and gel extraction using the Nucleospin extraction kit
(Macherey & Nagel). Sequencing of libraries was per-
formed at the Genome Center Cologne of the Max-Planck-
Society according to established protocols on an
HiSEQ2000 machine (Illumina) at a depth of 150 Mio
reads in total. For primer sequences and graphical repre-
sentation of the protocol, see supplementary table.
Processing of reads and bioinformatic analysis
FastQ files were converted into fastA files with the
FASTQ-to-FASTA converter and split into pools according
to barcodes using the FASTQ/A Barcode splitter (both
tools were from http://hannonlab.cshl.edu/fastx_toolkit/),
trimmed to 35 bases and mapped to the mouse using the
Mus musculus NCBI Built 37.1. Differential expression
analysis was performed using the Bioconductor package
DESeq (Version 1.4.1) (Anders and Huber 2010).
Results
Weak astroglial SR101-labeling in the brainstem
In an initial set of experiments, we compared SR101
staining from different regions of the brainstem, midbrain
and hippocampus using [TgN (hGFAP-EGFP)] mice at
ages between P8 and P23. The SR101 intensity in all the
tested regions of the brainstem was weak, especially when
compared with the labeling in the hippocampus (Fig. 1).
There was some regional heterogeneity also within the
brainstem, with more intense labeling in the lateral superior
olive (LSO; Fig. 1k), but altogether the SR101-labeling of
EGFP-positive astrocytes was far below the level in hip-
pocampal EGFP-positive cells. Additionally, we tested
SR101-labeling along the rostral–caudal extension of the
cortex of sagittal slices (Fig. 2). The astroglial SR101-
labeling at the three tested cortical areas was indistin-
guishable from each other. Thus, this test proved that our
approach of sorting EGFP-positive astrocytes from hippo-
campus (Hi) (and cortex; Cx) and brainstem will be valid to
detect a putative transporter for SR101.
Differential expression of Oatp1c1 in astrocytes
from forebrain over brainstem
Based on the hypothesis that the putative SR101 trans-
porter belongs to the solute carrier (organic anion trans-
porter) family (Schnell et al. 2012), we focused the analysis
of our next-generation sequencing results on these genes
(slc or slco gene symbols). Comparing the mRNA levels of
astrocytes from hippocampus (Hi), cortex (Cx) and brain-
stem (BS), we identified 359 transporter mRNAs (mapped
refSeq IDs, see methods) coding for 276 proteins that were
expressed at least in one of the three different regions (C10
reads, see supplementary table). However, we detected
only seven mRNAs encoding for five transporters of solute
carrier families including the glial glutamate transporter 1
(Glt1/Slc1a2), the sodium calcium exchanger (Ncx2/
Slc8a2) and the vesicular glutamate transporter 1 (Vglut1/
Slc17a7) that were expressed higher in the forebrain (Cx
and Hi) vs. brainstem astrocytes (Fig. 3d). There was no
organic anion transporter (OAT; Slc22 family) among
these genes, but from the Slco family, we found mRNAs
for two isoforms of the organic anion transporting poly-
peptide (Oatp)1c1 (Slco1c1) that were differentially
expressed between forebrain and brainstem astrocytes ([2
fold increase, adjusted p value \0.05). Additionally there
were ten genes that showed higher mRNA levels in the
brainstem as compared to the Cx and Hi, including the
known astroglial transporters for inhibitory neurotrans-
mitter, GAT3 (encoded by Slc6a11) and GlyT1 (encoded
by Slc6a9; supplementary table.)
Thyroid hormone inhibition of SR101-labeling
in hippocampal astrocytes
Oatp1c1/Slco1c1 has been identified to code for a thyroid
hormone transporter(OATP14, OATP-F; Pizzagalli et al.
2002) and, indeed, this candidate was the only one with a very
similar pharmacological profile (Sugiyama et al. 2003) as
described for the putative SR101 uptake system in hippo-
campal slices (Schnell et al. 2012). To test if the physiological
substrate of OATP1C1, L-thyroxine (T4), can compete with
the SR101 uptake, we incubated acute hippocampal slices
(P21–P22) in SR101 in the presence of different concentra-
tions of T4 (1–10 lM; n = 4). The intensity of SR101 fluo-
rescence in EGFP-labeled astrocytes of the stratum radiatum
was significantly reduced in a dose-dependent manner
(Fig. 4a–e). The relative number of EGFP-positive cells,
which showed some detectable, although very low level of
SR101 fluorescence (SR101-positive cells), however, did not
follow this dose dependency (Fig. 4f). Taken together, the
observed reduction in intensity of SR101-labeling supported
our hypothesis that OATP1C1 is the transporter responsible
for SR101 uptake into astrocytes.
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Fig. 1 SR101 uptake in various
regions of the forebrain and
hindbrain. a–c Coronal
diagrams of the brain section
analyzed; d schematic drawing
showing rostro-caudal position
of diagrams a–c (panels a–
d were adapted and modified
from the Paxinos Atlas of the
developing mouse brain
(Paxinos 2007). e–p Figures are
maximal intensity projections of
3D 2-photon scans (100 lm z-
stack, 51 sections) taken from
mice at P8. e0–p0 The
corresponding EGFP expression
is shown below the SR101
image. CA1 corpus ammonis of
hippocampus, APT anterior
pretectal nucleus, Po posterior
thalamic nuclear group, PnC
pontine reticular nucleus, caudal
part, 5N motor trigeminal
nucleus, LSO lateral superior
olive, Pr5VL principal sensory
trigeminal nucleus, ventrolateral
part, py pyramidal tract, pBC
pre-Bo¨tzinger complex, 12N
hypoglossal nucleus, IO inferior




Lack of SR101-labeling of astrocytes from Oatp1c1
knockout mice
To further substantiate this assumption that OATP1C1 is
the astroglial SR101-uptake transporter, we analyzed
SR101 uptake in Oatp1c1 null mutant (Slco1c1-/-) mice
(Mayerl et al. 2012). In hippocampal slices from
Slco1c1-/- mice, the identification of astrocytes by
SR101 is impossible (Fig. 4g–h). Since we could not
identify any SR101-labeled cell that morphologically
resembled an astrocyte, we further concluded that the weak
labeling observed in astrocytes of the ventrolateral medulla
(Schnell et al. 2012) could in fact result from the low,
albeit robustly detected level of expression of Oatp14/
Slco1c1 in the brainstem compared to hippocampus and
cortex (Fig. 3d). In this context, it is interesting to note that
the unspecific labeling that we sometimes observed in the
superficial neurons of the CA1 pyramidal layer (Fig. 4 and
supplementary movie) can still be observed after T4
application (Fig. 4b) and in the knockout slices (Fig. 4h).
Discussion
SR101 uptake in hippocampal astrocytes is mediated
by OATP1C1
Oatp1c1/Slco1c1 cDNA, coding for OATP1C1 that is also
known as OATP-F and OATP14, was cloned in 2008 as part
of the blood–brain barrier genome program (Chu et al.
2008). This high-affinity transporter for thyroxine (T4) acts
sodium-independently in a bidirectional manner (Pizzagalli
et al. 2002; Sugiyama et al. 2003; Tohyama et al. 2004).
Apart from T4, other OATP1C1 substrates, like probenecid,
estrone-3-sulfate (Tohyama et al. 2004) or dehydroepian-
drosterone (Sugiyama et al. 2003) reduced SR101 uptake in
hippocampal slices (Schnell et al. 2012). Although
OATP1C1 expression on the endothelial side of the blood–
brain barrier is established, the function of OATP1C1 as a
putative astrocytic transporter for T4 uptake is still under
debate (Grijota-Martı´nez et al. 2011; Ridder et al. 2011;
Heuer and Visser 2013). Our experiments finally prove the
expression of OATP1C1 in subpopulations of astrocytes.
Moreover, the overlap of OATP1C1 expression with Aqu-
aporin 4 (Roberts et al. 2008) suggests a preferential tar-
geting of the transporter to astroglial end feet of the blood
brain barrier. This polarized expression of OATP1C1
expression on end feet together with the endothelial
Fig. 2 Comparison of SR101 uptake along the rostral–caudal exten-
sion of the cortex. a Schematic drawing showing rostro-caudal
position of images b–e (panel a was adapted and modified from the
Paxinos Atlas (Paxinos et al. 2001). b–e SR101-labeling as maximal
intensity projections of the 3D two-photon scan (100 lm z-stack, 51
sections) from b the frontal associative cortex (FC), c motor cortex
(MC) and d visual cortex (VC). Scans were taken from parasagittal
slices (P10, 1–2 mm lateral to the midline). Additionally, a maximal
intensity projection image from the hippocampus (Hi) is depicted in
(e). b0–e0 The corresponding EGFP expression is shown next to the




expression (Fig. 5) explains why SR101 can cross the blood
brain barrier and label astrocytes when injected into the
vasculature (Appaix et al. 2012). The absence of astroglial
SR101-labeling in the Oatp1c1-/- mice suggests that
exclusively OATP1C1 mediates astrocytic SR101 uptake in
hippocampal astrocytes.
A general, region-specific heterogeneity of astrocytes
Our next-generation sequencing (NGS) approach not only
allows us to identify the uptake transporter for SR01 that
explains the region-specific differences of SR101-labeling
observed in the cardio-respiratory regions of the brainstem
(Schnell et al. 2012), but also sheds some light on a more
general heterogeneity of astrocytes. We could detect dif-
ferences in the expression of neurotransmitter transporters
that have already been reported before as for the glycine
transporter 1 (Slc6a9), GAT3 (Slc6a11) or the glial gluta-
mate transporter GLT1 (Slc1a2), a finding that underscores
the reliability of our method (Supplementary table). Since
expression of the transporter apparently correlates with the
importance of the different transmitter systems in these brain
regions, it is tempting to speculate that differential expres-
sion of the OATP1C1 across the forebrain and brainstem is
based on a more active involvement of forebrain astrocytes
in the control of local thyroid hormone metabolism.
Interestingly, in parallel to the forebrain-enriched
expression of the astroglial thyroid hormone transporter
Fig. 3 Identification of transporter genes enriched in forebrain
astrocytes by transcriptome analysis. a Experimental strategy: cortex
(Cx), hippocampus (Hi) and brainstem (Bs) tissues from brains of
mice expressing EGFP under the control of the glial-specific promoter
GFAP (hGFAP-EGFP) were triturated and 50 k EGFP-positive cells
were purified by FACS, followed by RNA isolation and transcriptome
profiling with RNAseq. SR101 candidate uptake transporter genes (of
the solute carrier, Slc family) were hypothesized to display a higher
expression in Cx and Hi versus Bs astrocytes (Cx/Hi [Bs). b Scatter
plots of FACS analysis with GFP intensities plotted versus forward
scatter (FSC) given as arbitrary units (a.u.). Blue dots represent
Hoechst 33,342 positive and GFP negative cells, green dots represent
Hoechst 33,342 and GFP double-positive cells representing different
astrocyte populations. c Venn diagram of all forebrain enriched
transporter genes. 27 (Cx) and 3 (Hi) refseq annotated mRNAs were
detected to be significantly higher expressed in Cx or Hi astrocytes
([2 fold change), and seven mRNAs were significantly elevated both
in Cx and Hi. d Differentially expressed mRNAs coding for solute
carriers (Slc and Slco gene families). The gene symbols, accession
and average read numbers in Cx, Hi and Bs samples are depicted. The
seven detected forebrain enriched mRNAs correspond to five genes
(Slc1a2 and Slco1c1 annotated by two mRNAs each). Detection
cutoff was determined with an adjusted p value cutoff \0.05. Cx
(n = 2), Hi (n = 3), Bs (n = 4) biological replicates
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Oatp1c1, we also found a higher expression of the type 2
iodothyronine deiodinase (Dio2), the enzyme that converts
thyroxine (T4) to 3,30,5-triiodothyronine (T3), in the cortex
and the hippocampus as compared to Bs (Cx 14,564, Hi
8,120, Bs 3,947 norm. reads; adjusted p values Cx vs. Bs
\0.001 and Hi vs. Bs = 0.0886). Further investigation will
be necessary to unveil the relevance of astroglial function
and eventually brain development, but the differential
expression of OATP1C1 appears to be a rather general
difference that is even preserved in humans. Indeed, human
OATP1C1 shows a region-specific expression with prefer-
ential detection of mRNA in the forebrain over the hind-
brain (Pizzagalli et al. 2002).
Methodological considerations
As in a preceding paper (Schnell et al. 2012), we observed
differences in the significance levels when comparing the
reduction of SR101 intensity, which was significant for all
T4 concentrations tested, with the apparent numbers of
SR101-labeled EGFP-positive astrocytes. Due to the man-
ual detection (see methods), which we found to be superior
to the automatic detection, all astrocytes with SR101
intensities that are just above the background are counted
and every EGFP-positive astrocyte with an incomplete
blockade of the transporter counts as an SR101-positive
cell. Therefore, we have to assume that the SR101 uptake by
the OATP1C1 is not completely blocked by the applied
concentrations of T4. However, in the Oatp1c1-/- slice,
we were unable to detect individual cell somata in the
SR101 channel, suggesting that there was no alternative
route of SR101 uptake in hippocampal astrocytes.
Our sequencing experiments were performed on FACS-
isolated EGFP-expressing cells from TgN (hGFAP-EGFP)
mice. The majority of the EGFP-expressing cells have been
proven to be astrocytes in the brain regions from which we
Fig. 4 The thyroid hormone transporter OATP1C1 (SLCO1C1) is
the astrocytic uptake transporter for SR101. a–d Maximal intensity
projections of SR101-labeling hippocampus slices from hGFAP-
EFGP mouse (P22) under control conditions (CTRL a) and in the
presence of 10 lM levothyroxine during the 20 min loading period
(T4 b). Corresponding EGFP fluorescence is shown in green below
the SR101 figure (c, d). e, f The basic statistical description of the
blockade of SR101 uptake by T4 is shown in (e) for the SR101
intensity as relative to the EGFP fluorescence. f Comparison of the
fraction of EGFP-positive astrocytes with a SR101-fluorescence
signal larger than background (SR101-positive astrocytes). Data are
given as mean ± SEM (n = 4 slices, four animals; one way ANOVA
with multiple comparisons versus Control Group; Bonferroni t test).
Significance is indicated by an asterisk for p \ 0.05. g, h SR101
uptake is diminished in Oatp1c1 knockout mice. While astrocytes
were labeled by SR101 in Hi slices from WT mice from the same
strain (three animals, n = 5 slices), no SR101-labeling was observed
in hippocampus slices from Slco1c1 KO mice (five animals; n = 15
slices). Note that the unspecific labeling in the superficial neurons of
the CA1 pyramidal layer (Thompson et al. 2006) is still present after
T4 and in the knockout slices
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took FACS samples (Nolte et al. 2001; Grass et al. 2004).
When interpreting the mRNA data, however, one must be
aware that the FACS-sorted EGFP-positive cells from the
hippocampus might include some neural precursors, e.g.,
from the subgranular zone of the dentate gyrus, which are
also EGFP positive (Hu¨ttmann et al. 2003). Additionally,
the EGFP-labeled cells population also includes a sub-
population of NG2-positive cells (oligodendrocyte precur-
sor cells) that also were shown to be EGFP-positive in the
hippocampus (Matthias et al. 2003; Jabs et al. 2005) as well
as in the brainstem (Grass et al. 2004; Szo¨ke et al. 2006).
For our aim, the identification of the SR101 transporter,
however, contamination with non-astrocyte cell popula-
tions was not critical, since we confirmed these results with
pharmacological experiments and by using the Slco1c1
knockout mouse.
Unspecific neuronal labeling in the CA1-pyramidal
layer
In some of our experiments, we noticed unspecific labeling
of pyramidal neurons close to the slice surface (see Fig. 3
and supplementary movie). Such unspecific neuronal
labeling has been reported before, although using different
labeling conditions, including lower temperature
(Nimmerjahn and Helmchen 2012) or reduced extracellular
magnesium concentration (Thompson et al. 2008) or
hypoxia (Thompson et al. 2006). From the observation that
unspecific staining was also found after application of T4 or
in the OATP1C-deficient situation (Fig. 4), one might
conclude that the unspecific neuronal staining results from
another mechanism that is not available or active in the
astrocyte. To answer the question whether this involves the
opening of pannexin hemichannels, as suggested (Thomp-
son et al. 2006, 2008), further experiments are requires that
are beyond the scope of the paper.
Perspectives
Although our study primarily aimed at identifying the
uptake mechanism of SR101 into astrocytes that underlies
the regional difference of SR101-labeling, we would like to
emphasize that by matching pharmacological properties
with cell type-specific expression profiles of transporters,
other dyes or compounds could be rationally designed and/
or identified to selectively target additional cell types of the
brain. Moreover, our strategy can pave the way toward a
rational design of cell type-selective dyes that may be used
for basic research purposes and also in the context of
diagnostic and therapeutic approaches for, e.g., gliomas,
Fig. 5 Schematic of the SR101-labeling mechanism. The figure
summarizes the mechanism of SR101-labeling in astrocytes. In slices
(left) SR101 is taken up into astrocytes that express the thyroid
hormone transporter OATP1C1 (Yellow). Uptake is blocked by
levothyroxine (T4; see Fig. 4a–f) and neurosteroids e.g., dehydroepi-
androsterone sulfate [DHEAS; (Schnell et al. 2012)]. Furthermore
(right in vivo), Oatp1c1 is also expressed on the vascular endothelium
(Ridder et al. 2011) allowing uptake of SR101 from the blood stream
(Appaix et al. 2012). Since SR101 still labels vessels in the Oatp1c1
knockout mouse (Fig. 4h), there might be a second transporter that
transports SR101 into the endothelium. Alternatively, there might be
also unspecific binding of SR101 to vasculature, as described, e.g., for
Alexa Fluor 633 (Shen et al. 2012)
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which often have special expression profiles for OATPs
(Bronger et al. 2005).
Conclusion
We have demonstrated that hippocampal astrocytes take up
sulforhodamine 101 via the thyroid hormone transporter
OATP1C1. This observation will help to understand the
possible side effects of SR101 application and prevent
pitfalls when using the drug in novel preparations or under
modified condition.
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